Early Phase 1 N=101 Dose Response Study of Aerobic Exercise in Older Adults
Alzheimer's Disease
Primary: Visuospatial Processing — -.02; .19; .08; .29 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=116 Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment
Colon Cancer · Colorectal Cancer · Rectal Cancer
Primary: Objective Response Rate at Weeks 17 and 25 — 20; 14; 22; 14 percentage of participants
Phase 4 N=307 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion
Retinal Vein Occlusion · Macular Edema
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) — 56.6; 59.2; 7.9; 16.9 letters
Phase 4 N=100 Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery
Pain
Primary: Efficacy of Pain Relief (Pain Intensity at Rest) — 30; 32 units on a scale (in mm)
N/A N=9 Using a Text-message System to Engage Depressed Adolescents in Cognitive-behavioral Therapy Homework
Major Depressive Disorder · Cognitive Behavior Therapy · Text Messaging
Primary: Therapy Homework Compliance: Percent Homework Completed — .44; 0; 0.47; 0.25 homework sheets completed
N/A N=145 A Clinical Study to Assess the Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence
Stress Urinary Incontinence
Primary: Treatment-emergent Serious Adverse Event — 0; 0 participants
Phase 2 N=102 Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee
Osteoarthritis, Knee
Primary: Change From Baseline in the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Score at 1 Year — 23.3; 9.9 scores on a scale — p=<0.01
N/A N=32 Clinical Evaluation of Daily Disposable Contact Lenses
Myopia
Primary: Overall Lens Preference - All Study Lenses — 5; 3; 8; 4 participants
Phase 2 N=181 Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26
Meningitis · Meningococcemia
Primary: Percentage of Participants With Serum Meningococcal Serogroups A, C, Y, and W-135 Bactericidal Antibody Titers ≥ 1:4 and ≥ 1:8 Before and Following Vaccination With…
Phase 4 N=1,034 A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough FEV1 on Day 85 — 0.123; 0.099 Liter — p=0.100
Phase 2 N=52 T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents
HIV Infections
Primary: Area Under the Plasma Concentration Time Curve (AUC) From 0-12 Hours for Enfuvirtide and Its Metabolite (Ro 50-6343) — 56.1; 52.7; 3.07; 3.41 microgram hour per…
Phase 2 N=28 Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction
Heart Disease · Heart Failure With Preserved Ejection Fraction · Exercise Intolerance
Primary: Exercise Pulmonary Capillary Wedge Pressure (PCWP) — 19.0; 28.0 mm Hg — p=0.0003
N/A N=270 A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients
Hepatitis C, Chronic
Primary: Percentage of Participants Achieving Sustained Virological Response (SVR) According to Genotype and Previous Treatment — 66; 51; 67; 75 percentage of participants
Phase 1 N=5 Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability
Dizziness
Primary: Change in Dynamic Gait Index (DGI) From Baseline to 6 Weeks. — 4.3 units on a scale
Phase 4 N=24 Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
Papulopustular Rosacea
Primary: Rosacea Score on the Visual Analog Scale — 4.50; 4.52; 3.77; 3.06 units on a scale